Lixte Biotechnology H -CW25LIXTWPreferred / convertible
13F holders, Q3 2025 (September 30)3holders −1
1new positions
2sold out
$0.14avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Lixte Biotechnology H -CW25 (LIXTW) in their 13F filings, down 1 from Q2 2025. 1 opened new positions and 2 sold out. The largest holders were Clear Street Group Inc. ($3K), NFSG Corp ($361) and UBS Group AG ($125).
- Company
- Lixte Biotechnology H -CW25
- CUSIP
- 539319111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $125 |
| Exits | 2 | $725 |
All 13F filers, Q2 2025 → Q3 2025: 867 shares bought and 25,331 shares sold, net −24,464 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street Group Inc. | — | — | 21,618 | $3K |
| NFSG Corp | — | No change | 2,500 | $361 |
| UBS Group AG | — | New | 867 | $125 |
"% of holder's portfolio" is LIXTW's weight in each manager's 13F, not the share of Lixte Biotechnology H -CW25 the manager owns.